| Year |
Citation |
Score |
| 2023 |
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, et al. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300296. PMID 37695982 DOI: 10.1200/JCO.23.00296 |
0.328 |
|
| 2022 |
Teng W, Jiang W, Chen BE. A nonparametric simultaneous confidence band for biomarker effect on the restricted mean survival time. Statistics in Medicine. PMID 36444774 DOI: 10.1002/sim.9618 |
0.785 |
|
| 2022 |
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, et al. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. Jama. 327: 1963-1973. PMID 35608580 DOI: 10.1001/jama.2022.6147 |
0.315 |
|
| 2022 |
Lohmann AE, Ennis M, Parulekar WR, Chen BE, Tomlinson G, Goodwin PJ. The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute. PMID 35377437 DOI: 10.1093/jnci/djac067 |
0.335 |
|
| 2021 |
Prica A, Hay AE, Crump M, Mittmann N, Shepherd LE, Meyer RM, Imrie KI, Risebrough N, Djurfeldt M, Chen BE, Cheung MC. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Current Oncology (Toronto, Ont.). 28: 1256-1261. PMID 33802634 DOI: 10.1182/Blood.V130.Suppl_1.4673.4673 |
0.352 |
|
| 2020 |
Dent SF, Botros J, Rushton M, Aseyev O, Levine MN, Parulekar WR, O'Brien P, Burnell M, Pritchard KI, Chen BE, Shepherd LE. Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. Breast Cancer Research and Treatment. PMID 32940847 DOI: 10.1007/S10549-020-05887-W |
0.409 |
|
| 2020 |
Moku P, Shepherd L, Ali SM, Leitzel K, Parulekar WR, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon K, Drabick J, Cream L, Halstead ES, Umstead TM, Mckeone D, ... ... Chen BE, et al. Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial. Cancer. PMID 32910476 DOI: 10.1002/Cncr.33149 |
0.379 |
|
| 2020 |
Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel J, Shepherd L, Hershman DL, Whelan T, Stambolic V, Mayer I, Hobday T, Lemieux J, Thompson A, Rastogi P, Gelmon K, et al. The effect of metformin vs placebo on sex hormones in CCTG MA.32. Journal of the National Cancer Institute. PMID 32497219 DOI: 10.1093/Jnci/Djaa082 |
0.394 |
|
| 2020 |
Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, van den Neste E, Shepherd LE, Schmitz N, Baetz T, Keating A, Robinson S, Seftel M, Stelitano C, Djurfeldt MS, Meyer R, ... Chen BE, et al. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. Blood Advances. 4: 2011-2017. PMID 32396614 DOI: 10.1182/Bloodadvances.2020001646 |
0.353 |
|
| 2020 |
Assouline S, Amrein L, Aloyz R, Banerji V, Caplan S, Owen C, Hasegawa W, Robinson S, Shivakumar S, Prica A, Peters A, Hagerman L, Rodriguez L, Skamene T, Panasci L, ... Chen BE, et al. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-7. PMID 32154751 DOI: 10.1080/10428194.2020.1734594 |
0.317 |
|
| 2020 |
Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching PA, Hoskin TL, Singh RJ, Desta Z, Kalari KR, Ellis MJ, Goss PE, Chen BE, Volz B, Barman P, Carlson EE, et al. Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32098767 DOI: 10.1158/1078-0432.Ccr-19-3091 |
0.339 |
|
| 2020 |
Tan X, Chen BE, Sun J, Patel T, Ibrahim JG. A hierarchical testing approach for detecting safety signals in clinical trials. Statistics in Medicine. PMID 32050050 DOI: 10.1002/Sim.8495 |
0.326 |
|
| 2020 |
Chen L, Tyryshkin K, Moore A, Scott DW, Steidl C, Li Y, Shepherd LE, Rauh M, Deng L, Good D, Virk S, Chen BE, Crocker S, Baetz T, LeBrun DP. Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and gene alterations. Leukemia & Lymphoma. 1-11. PMID 31942813 DOI: 10.1080/10428194.2020.1713318 |
0.322 |
|
| 2019 |
Chen BE, Wang J. Joint modeling of binary response and survival for clustered data in clinical trials. Statistics in Medicine. PMID 31777115 DOI: 10.1002/Sim.8403 |
0.39 |
|
| 2019 |
Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, et al. Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. Pharmacogenetics and Genomics. PMID 31211741 DOI: 10.1097/Fpc.0000000000000382 |
0.357 |
|
| 2019 |
Hoch JS, Hay A, Isaranuwatchai W, Thavorn K, Leighl NB, Tu D, Trenaman L, Dewa CS, O'Callaghan C, Pater J, Jonker D, Chen BE, Mittmann N. Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. Bmc Cancer. 19: 552. PMID 31174497 DOI: 10.1186/S12885-019-5779-X |
0.41 |
|
| 2019 |
Gross JP, Whelan TJ, Parulekar WR, Chen BE, Rademaker AW, Helenowski IB, Donnelly ED, Strauss JB. Development and validation of a nomogram to predict lymphedema following axillary surgery and radiotherapy in women with breast cancer from the NCIC CTG MA.20 randomized trial. International Journal of Radiation Oncology, Biology, Physics. PMID 31085285 DOI: 10.1016/J.Ijrobp.2019.05.002 |
0.371 |
|
| 2019 |
Parulekar WR, Berrang T, Kong I, Rakovitch E, Theberge V, Gelmon KA, Chia SKL, Bellon JR, Jagsi R, Ho AY, White JR, Zellars RC, Bane A, Boileau J, Lemieux J, ... ... Chen BE, et al. Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps602 |
0.395 |
|
| 2019 |
Pimentel I, Chen BE, Lohmann AE, Ennis M, Ligibel JA, Shepherd LE, Hershman DL, Stambolic V, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Rastogi P, Gelmon KA, Whelan TJ, et al. The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy. Journal of Clinical Oncology. 37: 529-529. DOI: 10.1200/Jco.2019.37.15_Suppl.529 |
0.398 |
|
| 2019 |
Moku PR, Shepherd LE, Ali S, Leitzel K, Parulekar WR, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Drabick J, Cream L, Halstead S, Polimera HV, Maddukuri A, ... ... Chen BE, et al. Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer. Journal of Clinical Oncology. 37: 1031-1031. DOI: 10.1200/Jco.2019.37.15_Suppl.1031 |
0.378 |
|
| 2019 |
Venner CP, Leblanc R, Sandhu I, White DJ, Belch A, Reece DE, Chen CI, Dolan S, Lalancette M, Louzada ML, Kew A, McCurdy A, Reiman T, Sherry M, McDonald GT, ... ... Chen BE, et al. Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma Blood. 134: 1871-1871. DOI: 10.1182/Blood-2019-122637 |
0.325 |
|
| 2019 |
Moku P, Shepherd L, Ali S, Leitzel K, Parulekar W, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon K, Drabick J, Cream L, Halstead S, Umstead T, Mckeone D, ... ... Chen B, et al. Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd3-10 |
0.316 |
|
| 2019 |
Parulekar W, Joy A, Gelmon K, Mates M, Desbiens C, Clemons M, Taylor S, Lemieux J, Bartlett J, Whelan T, Ayoub J, Cescon D, Bordeleau L, Rahim Y, Winch C, ... Chen B, et al. Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd1-10 |
0.387 |
|
| 2018 |
Spreafico A, Sultanem K, Chen B, Bratman SV, Ringash J, Louie AV, McNiven A, Whelan K, Hilton J, Yoo J, Machiels JP, Licitra LF, Oosting S, Waldron JN, Siu LL, et al. A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii399. PMID 32136992 DOI: 10.1093/Annonc/Mdy287.080 |
0.379 |
|
| 2018 |
Baetz TD, Song X, Ernst DS, McWhirter E, Petrella TM, Savage KJ, Smylie M, Wong R, Lee CW, Hong NL, Logan D, Raza MS, Abbas T, Nomikos D, Leung R, ... Chen BE, et al. A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps9600 |
0.307 |
|
| 2018 |
Skamene T, Siu LL, Renouf DJ, Laskin JJ, Bedard PL, Jones SJM, Ferrario C, Whitlock J, Petrie J, Sullivan P, Malone ER, Nomikos D, Chen BE, Dancey J. Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps12127 |
0.327 |
|
| 2018 |
Hay AE, Crump M, Skrabek P, Cheung MC, Grewal K, Sabry W, Chalchal HI, Sharif I, Cantin G, Pavic M, Snyder J, Broekhoven M, Djurfeldt M, Shepherd LE, Meyer RM, ... Chen BE, et al. Prospective linkage of clinical trial and administrative databases: Acceptability to patients and research ethics boards. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E18692 |
0.333 |
|
| 2018 |
Monteith B, DiMaria EC, Crump M, Ames JB, Winter JN, Djurfeldt M, Shepherd LE, Meyer RM, Chen BE, Hay AE. Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial. Journal of Clinical Oncology. 36: 7535-7535. DOI: 10.1200/Jco.2018.36.15_Suppl.7535 |
0.36 |
|
| 2018 |
Paggio JD, Fundytus AM, Hopman WM, Pater JL, Chen BE, Brundage MD, Hay AE, Booth CM. A value framework analysis of the Canadian Cancer Trials Group. Journal of Clinical Oncology. 36: 6614-6614. DOI: 10.1200/Jco.2018.36.15_Suppl.6614 |
0.361 |
|
| 2018 |
Dowling RJ, Parulekar WR, Gelmon KA, Shepherd LE, Virk S, Ennis M, Mao F, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Rabaglio-Poretti M, ... ... Chen BE, et al. CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC). Journal of Clinical Oncology. 36: 557-557. DOI: 10.1200/Jco.2018.36.15_Suppl.557 |
0.354 |
|
| 2018 |
Venner CP, Leblanc R, Sandhu I, White DJ, Belch AR, Reece DE, Chen CI, Dolan S, Kew A, Lalancette M, Louzada ML, McCurdy A, McDonald GT, Reiman T, Rodriguez L, ... ... Chen BE, et al. MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies Blood. 132: 1984-1984. DOI: 10.1182/Blood-2018-99-117824 |
0.362 |
|
| 2018 |
Dehghani Mohammadabadi M, Hay AE, Shepherd LE, Crump M, Chen BE, Baetz T. Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of
Canadian Cancer Trials Group (CCTG)
ly.10 Trial Blood. 132: 2980-2980. DOI: 10.1182/Blood-2018-99-116316 |
0.396 |
|
| 2017 |
Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Parulekar WR, Liedke PER, Chen BE, Goss PE. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. European Journal of Cancer (Oxford, England : 1990). 90: 19-25. PMID 29274617 DOI: 10.1016/J.Ejca.2017.11.014 |
0.354 |
|
| 2017 |
Bosch M, Akhter A, Chen BE, Mansoor A, Lebrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA. A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma. Haematologica. PMID 29097500 DOI: 10.3324/Haematol.2017.179309 |
0.348 |
|
| 2017 |
Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Jama Oncology. e172085. PMID 28750133 DOI: 10.1001/Jamaoncol.2017.2085 |
0.396 |
|
| 2017 |
Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, ... ... Chen BE, et al. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study(). Leukemia & Lymphoma. 1-9. PMID 28504033 DOI: 10.1080/10428194.2017.1312379 |
0.37 |
|
| 2017 |
Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, ... ... Chen BE, et al. Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment. PMID 28447237 DOI: 10.1007/S10549-017-4265-X |
0.357 |
|
| 2017 |
Ghate K, Parulekar WR, Chen BE, Montenegro A, Khaouam N, McCarthy JS, Walker J, Waldron J, Siu LL, Johnson A. Resource utilization in patients with head and neck cancer: Analysis of CCTG HN6 (NCT00820248). Journal of Clinical Oncology. 35: 6067-6067. DOI: 10.1200/Jco.2017.35.15_Suppl.6067 |
0.364 |
|
| 2017 |
Kang A, Hupp M, Ho D, Huang J, Leitzel K, Ali S, Shepherd L, Parulekar W, Ellis C, Rocco C, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon K, ... ... Chen B, et al. Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31 Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-07-06 |
0.383 |
|
| 2017 |
Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar W, Shepherd L, Gelmon K, Nielsen T. Abstract P1-09-08: Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31 Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-09-08 |
0.335 |
|
| 2017 |
Fang T, Mackillop WJ, Jiang W, Hildesheim A, Wacholder S, Chen BE. A Bayesian method for risk window estimation with application to HPV vaccine trial Computational Statistics & Data Analysis. 112: 53-62. DOI: 10.1016/J.Csda.2017.02.011 |
0.619 |
|
| 2017 |
Gavanji P, Chen BE, Jiang W. Residual Bootstrap Test for Interactions in Biomarker Threshold Models with Survival Data Statistics in Biosciences. 10: 202-216. DOI: 10.1007/S12561-017-9211-2 |
0.669 |
|
| 2017 |
Kuruvilla J, Crump M, Villa D, Aslam M, Prica A, Scott DW, Abdel‐Samad N, Couban S, Doucet S, Dudebout J, Fleury I, Fraser G, Larouche J, Shafey M, Skrabek P, ... ... Chen BE, et al. Canadian Cancer Trials Group (Cctg) Ly.17: A Randomized Phase Ii Study Evaluating Novel Salvage Therapy Pre‐Autologous Stem Cell Transplant (Asct) In Relapsed/Refractory Diffuse Large B Cell Lymphoma (Rr‐Dlbcl) ‐ Outcome Of Ibrutinib + R‐Gdp Hematological Oncology. 35: 88-88. DOI: 10.1002/Hon.2437_76 |
0.329 |
|
| 2016 |
Ringash J, Waldron JN, Siu LL, Martino R, Winquist E, Wright JR, Nabid A, Hay JH, Hammond A, Sultanem K, Hotte S, Leong C, El-Gayed AA, Naz F, Ramchandar K, ... ... Chen BE, et al. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). European Journal of Cancer (Oxford, England : 1990). 72: 192-199. PMID 28040660 DOI: 10.1016/J.Ejca.2016.11.008 |
0.303 |
|
| 2016 |
Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein N, Kaizer L, Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the Phase III CCTG LY.12 Trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27993811 DOI: 10.1093/Annonc/Mdw653 |
0.344 |
|
| 2016 |
Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, et al. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. Jama Oncology. PMID 27930762 DOI: 10.1001/Jamaoncol.2016.4510 |
0.334 |
|
| 2016 |
Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce JP, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss GD, ... ... Chen BE, et al. BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27827316 DOI: 10.1158/1078-0432.Ccr-16-1640 |
0.328 |
|
| 2016 |
South A, Parulekar WR, Sydes MR, Chen BE, Parmar MK, Clarke N, Warde P, Mason M. Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. European Urology Focus. 2: 276-283. PMID 27766313 DOI: 10.1016/J.Euf.2015.11.004 |
0.349 |
|
| 2016 |
Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Research. PMID 27758888 DOI: 10.1158/0008-5472.Can-16-1371 |
0.38 |
|
| 2016 |
Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, ... ... Chen BE, et al. A pharmacogenetic analysis of the Canadian Cancer Trials Group (NCIC CTG) MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood. PMID 27338095 DOI: 10.1182/Blood-2016-06-716902 |
0.389 |
|
| 2016 |
Spears M, Lyttle N, D'Costa A, Chen BE, Yao CQ, Boutros PC, Burnell M, Levine MN, O'Brien P, Shepherd L, Bartlett JM. A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. Oncotarget. PMID 27056899 DOI: 10.18632/Oncotarget.8542 |
0.425 |
|
| 2016 |
Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statistics in Medicine. PMID 26887976 DOI: 10.1002/Sim.6907 |
0.416 |
|
| 2016 |
Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, ... ... Chen BE, et al. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiology. 41: 50-56. PMID 26816351 DOI: 10.1016/J.Canep.2015.12.012 |
0.368 |
|
| 2016 |
Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Chen BE, Parulekar WR, Liedke PER, Goss PE. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA.27. Journal of Clinical Oncology. 34: 521-521. DOI: 10.1200/Jco.2016.34.15_Suppl.521 |
0.388 |
|
| 2016 |
Dent SF, Aseyev O, Levine MN, Pritchard KI, Parulekar WR, Chen BE, O'Brien P, Burnell MJ, Shepherd LE. Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience. Journal of Clinical Oncology. 34: 1016-1016. DOI: 10.1200/Jco.2016.34.15_Suppl.1016 |
0.326 |
|
| 2016 |
Skamene T, Jiang W, Meyer RM, Crump M, Kuruvilla J, Kouroukis CT, Luminari S, Couban S, Cheung MC, Rizzieri DA, Bardy PG, Pater J, Djurfeldt MS, Shepherd LE, Chen BE, et al. Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial Blood. 128: 690-690. DOI: 10.1182/Blood.V128.22.690.690 |
0.351 |
|
| 2016 |
Jiang W, Moon NC, Chen BE, Tu D. Permutation Methods for Comparing the Accuracy of Nested Prediction Models in Survival Analysis Communications in Statistics: Simulation and Computation. 45: 2691-2708. DOI: 10.1080/03610918.2014.920877 |
0.667 |
|
| 2015 |
Lin LA, Luo S, Chen BE, Davis BR. Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions. Statistical Methods in Medical Research. PMID 26546256 DOI: 10.1177/0962280215613378 |
0.328 |
|
| 2015 |
Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. European Journal of Cancer (Oxford, England : 1990). PMID 26338195 DOI: 10.1016/J.Ejca.2015.08.004 |
0.3 |
|
| 2015 |
Bartlett JM, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE, Shepherd LE, Chapman JW. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial. British Journal of Cancer. 113: 722-8. PMID 26284338 DOI: 10.1038/Bjc.2015.271 |
0.362 |
|
| 2015 |
Kuruvilla J, MacDonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, Anglin P, Seftel M, Ismail WS, Luminari S, Couban S, Baetz T, Meyer RM, Hay AE, Shepherd L, ... ... Chen BE, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. PMID 26109202 DOI: 10.1182/Blood-2015-01-622084 |
0.328 |
|
| 2015 |
Liu Y, Jiang W, Chen BE. Testing for treatment-biomarker interaction based on local partial-likelihood. Statistics in Medicine. PMID 26084729 DOI: 10.1002/Sim.6563 |
0.7 |
|
| 2015 |
Brundage M, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, Kirkbride P, Parliament M, Moynihan C, Bahary JP, Parmar MK, Sanders K, Chen BE, Mason MD. Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2151-7. PMID 26014295 DOI: 10.1200/Jco.2014.57.8724 |
0.34 |
|
| 2015 |
Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer D, Desjardins P, ... ... Chen BE, et al. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. Journal of the National Cancer Institute. 107. PMID 25868579 DOI: 10.1093/Jnci/Djv106 |
0.315 |
|
| 2015 |
Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, ... ... Chen BE, et al. Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. Journal of the National Cancer Institute. 107. PMID 25740979 DOI: 10.1093/Jnci/Djv006 |
0.374 |
|
| 2015 |
Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, ... ... Chen BE, et al. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2143-50. PMID 25691677 DOI: 10.1200/Jco.2014.57.7510 |
0.323 |
|
| 2015 |
Cuffe S, Hon H, Tobros K, Espin-Garcia O, Brhane Y, Harland L, Fadhel E, Eng L, LaDelfa A, Waldron J, Siu LL, Chen BE, Xu W, Simmons C, Kassam Z, et al. Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial. Clinical Trials (London, England). 12: 237-45. PMID 25633805 DOI: 10.1177/1740774514568689 |
0.412 |
|
| 2015 |
Ringash J, Waldron JN, Siu LL, Martino R, Winquist E, Wright JR, Nabid A, Hay JH, Hammond A, Sultanem K, Hotte S, Leong C, El-Gayed AAH, Naz F, Ramchandar K, ... ... Chen BE, et al. Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). Journal of Clinical Oncology. 33: 6053-6053. DOI: 10.1200/Jco.2015.33.15_Suppl.6053 |
0.313 |
|
| 2015 |
Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, et al. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. Journal of Clinical Oncology. 33: 6000-6000. DOI: 10.1200/Jco.2015.33.15_Suppl.6000 |
0.342 |
|
| 2015 |
Ramjeesingh R, Kankesan J, Chen BE, Pater JL, Han L, O'Brien P, Burnell MJ, Shepherd LE, Parulekar WR. Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222). Journal of Clinical Oncology. 33: 1033-1033. DOI: 10.1200/Jco.2015.33.15_Suppl.1033 |
0.337 |
|
| 2015 |
Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Chen BE, Djurfeldt M, et al. A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma Blood. 126: 2960-2960. DOI: 10.1182/Blood.V126.23.2960.2960 |
0.345 |
|
| 2015 |
Ellis MJ, Chen B, Chapman JW, Luo J, Ma D, Shepherd L, Hoog J, Leung S, Mardis E, Davies SR, Nielsen TO, Bramwell V. Abstract P4-11-11: CADER prognostic gene signature for disease free survival in hormone receptor positive breast cancer: NCIC CTG MA.12 phase III placebo-controlled tamoxifen trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-11-11 |
0.433 |
|
| 2015 |
Ramjeesingh R, Chen BE, Pater JL, Zhu L, Burnell M, Bramwell VH, Pritchard KI, Shepherd LE, Parulekar WR. Abstract P3-09-02: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-09-02 |
0.443 |
|
| 2014 |
Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee S, ... ... Chen BE, et al. Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). Journal of Clinical Oncology. 32: 542-542. DOI: 10.1200/Jco.2014.32.15_Suppl.542 |
0.346 |
|
| 2014 |
Hay AE, Monzon JG, McDonald GT, Pater JL, Meyer RM, Chen EX, Chen BE, Dancey J. Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. Journal of Clinical Oncology. 32: 2549-2549. DOI: 10.1200/Jco.2014.32.15_Suppl.2549 |
0.344 |
|
| 2014 |
Cuffe S, Hon H, Tobros K, Espin-Garcia O, Brhane Y, Harland L, Fadhel E, Eng L, LaDelfa A, Waldron JN, Chen BE, Xu W, Simmons CE, Kassam Z, Siu LL, et al. Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial: A patient preference study and subanalysis of the NCIC clinical trials group HN.6 clinical trial. Journal of Clinical Oncology. 32: 1586-1586. DOI: 10.1200/Jco.2014.32.15_Suppl.1586 |
0.428 |
|
| 2014 |
Baetz T, Chen BE, Couban S, Kouroukis CT, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Turner R, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12 Blood. 124: 1712-1712. DOI: 10.1182/Blood.V124.21.1712.1712 |
0.301 |
|
| 2014 |
Chen BE, Jiang W, Tu D. A hierarchical Bayes model for biomarker subset effects in clinical trials Computational Statistics and Data Analysis. 71: 324-334. DOI: 10.1016/J.Csda.2013.05.015 |
0.682 |
|
| 2013 |
Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 3065-9. PMID 24121121 DOI: 10.1093/Annonc/Mdt389 |
0.304 |
|
| 2013 |
Petrella TM, Mihalcioiu CLD, McWhirter E, Belanger K, Savage KJ, Song X, Hamid O, Cheng T, Davis ML, Lee CW, Spatz A, Monzon JG, Hagerman L, Chen BE, Dancey J. Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). Journal of Clinical Oncology. 31: 9032-9032. DOI: 10.1200/Jco.2013.31.15_Suppl.9032 |
0.355 |
|
| 2013 |
Goodwin PJ, Parulekar W, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, ... ... Chen BE, et al. Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). Journal of Clinical Oncology. 31: 1033-1033. DOI: 10.1200/Jco.2013.31.15_Suppl.1033 |
0.345 |
|
| 2013 |
Kuruvilla J, Kouroukis CT, Benger A, Cheung MC, Berinstein NL, Couban S, Seftel MD, Howson-Jan K, Keating A, Federico M, Macdonald DA, Olney HJ, Rubinger M, Voralia M, Turner AR, ... ... Chen B, et al. A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12 Blood. 122: 155-155. DOI: 10.1182/Blood.V122.21.155.155 |
0.327 |
|
| 2013 |
Chow E, Linden YVD, Roos D, Hartsell W, Hoskin P, Wu J, Brundage M, Meyer R, Chen B, Wong R. Response and Quality of Life (QOL) Outcomes in a Randomized Trial of Single Versus Multiple Fractions (Fx) for Re-irradiation (RE-RT) of Painful Bone Metastases (PBM): NCIC CTG SC.20 International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.022 |
0.335 |
|
| 2013 |
Jiang W, Chen BE. Estimating prediction error in microarray classification: Modifications of the 0.632+ bootstrap when n < p Canadian Journal of Statistics. 41: 133-150. DOI: 10.1002/Cjs.11158 |
0.614 |
|
| 2012 |
Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. The New England Journal of Medicine. 366: 399-408. PMID 22149921 DOI: 10.1056/Nejmoa1111961 |
0.313 |
|
| 2012 |
Waldron JN, Parulekar W, O'Sullivan B, Chen BE, Montenegro A, Nabid A, Winquist E, Wright JR, Hay J, Ringash J, Martino R, Johnson A, Liu G, Breen S, Gilbert RW, et al. A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps5600 |
0.313 |
|
| 2012 |
Mason MD, Parulekar W, Sydes MR, Parmar M, Anderson J, Barber J, Brundage MD, Cowan R, Gospodarowicz MK, Hayter C, Hetherington J, Hiltz AC, Kirkbride P, Kostashuk E, Sanders K, ... ... Chen BE, et al. Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110). Journal of Clinical Oncology. 30: 4509-4509. DOI: 10.1200/Jco.2012.30.15_Suppl.4509 |
0.347 |
|
| 2012 |
Jamal R, Chen BE, Hristova G, Seymour L, Assouline SE. Predictive model for survival and toxicity in early-phase trials in hematology. Journal of Clinical Oncology. 30: 2547-2547. DOI: 10.1200/Jco.2012.30.15_Suppl.2547 |
0.356 |
|
| 2012 |
Crump M, Kuruvilla J, Couban S, Macdonald D, Kukreti V, Kouroukis CT, Meyer RM, Rubinger M, Buckstein R, Imrie KR, Federico M, Renzo ND, Howson-Jan K, Baetz T, Kaizer L, ... ... Chen BE, et al. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12 Blood. 120: 745-745. DOI: 10.1182/Blood.V120.21.745.745 |
0.354 |
|
| 2012 |
Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz M, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, et al. Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone Blood. 120: 548-548. DOI: 10.1182/Blood.V120.21.548.548 |
0.335 |
|
| 2012 |
Gospodarowicz MK, Mason M, Parulekar W, Swanson G, Kirkbride P, Brundage M, Sydes M, Hetherington J, Chen B, Warde P. Final Analysis of Intergroup Randomized Phase III Study of Androgen Deprivation Therapy (ADT) ± Radiation Therapy (RT) in Locally Advanced Prostate Cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633) International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.020 |
0.31 |
|
| 2011 |
Parulekar W, Chen BE, Elliott C, Shepherd LE, Gelmon KA, Pritchard KI, Whelan TJ, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Rastogi P, Lemieux J, Ganz PA, Stambolic V, et al. A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS103. PMID 28022859 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps103 |
0.376 |
|
| 2011 |
Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3396-401. PMID 21810681 DOI: 10.1200/Jco.2010.33.6594 |
0.326 |
|
| 2011 |
Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment. 126: 215-20. PMID 20976543 DOI: 10.1007/S10549-010-1224-1 |
0.41 |
|
| 2011 |
Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6 Blood. 118: 590-590. DOI: 10.1182/Blood.V118.21.590.590 |
0.428 |
|
| 2009 |
Shen M, Chapman RS, Vermeulen R, Tian L, Zheng T, Chen BE, Engels EA, He X, Blair A, Lan Q. Coal use, stove improvement, and adult pneumonia mortality in Xuanwei, China: a retrospective cohort study. Environmental Health Perspectives. 117: 261-6. PMID 19270797 DOI: 10.1289/Ehp.11521 |
0.3 |
|
| 2009 |
Park SK, Andreotti G, Sakoda LC, Gao YT, Rashid A, Chen J, Chen BE, Rosenberg PS, Shen MC, Wang BS, Han TQ, Zhang BH, Yeager M, Chanock S, Hsing AW. Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. Carcinogenesis. 30: 606-14. PMID 19168589 DOI: 10.1093/Carcin/Bgp024 |
0.573 |
|
| 2009 |
Chen BE, Cook RJ. The analysis of multivariate recurrent events with partially missing event types. Lifetime Data Analysis. 15: 41-58. PMID 18622700 DOI: 10.1007/S10985-008-9091-3 |
0.486 |
|
| 2009 |
Sehn LH, Macdonald DA, Rubin SH, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie KR, Gascoyne RD, Chen B, Djurfeldt M, Shepherd L, Couban S, Crump M. Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group. Blood. 114: 407-407. DOI: 10.1182/Blood.V114.22.407.407 |
0.33 |
|
| 2008 |
Hsing AW, Sakoda LC, Rashid A, Andreotti G, Chen J, Wang BS, Shen MC, Chen BE, Rosenberg PS, Zhang M, Niwa S, Chu L, Welch R, Yeager M, Fraumeni JF, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Research. 68: 6442-52. PMID 18676870 DOI: 10.1158/0008-5472.Can-08-0444 |
0.558 |
|
| 2008 |
Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. Bmc Genetics. 9: 36. PMID 18477402 DOI: 10.1186/1471-2156-9-36 |
0.49 |
|
| 2008 |
Chang SC, Rashid A, Gao YT, Andreotti G, Shen MC, Wang BS, Han TQ, Zhang BH, Sakoda LC, Leitzmann MF, Chen BE, Rosenberg PS, Chen J, Chanock SJ, Hsing AW. Polymorphism of genes related to insulin sensitivity and the risk of biliary tract cancer and biliary stone: a population-based case-control study in Shanghai, China. Carcinogenesis. 29: 944-8. PMID 18375961 DOI: 10.1093/Carcin/Bgn025 |
0.555 |
|
| 2008 |
Andreotti G, Chen J, Gao YT, Rashid A, Chen BE, Rosenberg P, Sakoda LC, Deng J, Shen MC, Wang BS, Han TQ, Zhang BH, Yeager M, Welch R, Chanock S, et al. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 525-34. PMID 18296645 DOI: 10.1158/1055-9965.Epi-07-2704 |
0.553 |
|
| 2008 |
Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, Chen BE, Chen J, Andriole GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, et al. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis. 29: 568-72. PMID 17999989 DOI: 10.1093/Carcin/Bgm253 |
0.323 |
|
| 2008 |
Huang WY, Gao YT, Rashid A, Sakoda LC, Deng J, Shen MC, Wang BS, Han TQ, Zhang BH, Chen BE, Rosenberg PS, Chanock SJ, Hsing AW. Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China. Carcinogenesis. 29: 100-5. PMID 17984110 DOI: 10.1093/Carcin/Bgm247 |
0.548 |
|
| 2008 |
Chen BE, Kramer JL, Greene MH, Rosenberg PS. Competing risks analysis of correlated failure time data. Biometrics. 64: 172-9. PMID 17680835 DOI: 10.1111/J.1541-0420.2007.00868.X |
0.583 |
|
| 2008 |
Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, Andersson M, Fossa SD, Joensuu H, Boice JD, Kleinerman RA, et al. Response: Re: Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk Journal of the National Cancer Institute. 100: 600-601. DOI: 10.1093/Jnci/Djn086 |
0.325 |
|
| 2007 |
Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, Andersson M, Fosså SD, Joensuu H, Boice JD, Kleinerman RA, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. Journal of the National Cancer Institute. 99: 1634-43. PMID 17971527 DOI: 10.1093/Jnci/Djm201 |
0.376 |
|
| 2007 |
Anderson WF, Chen BE, Brinton LA, Devesa SS. Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer Causes & Control : Ccc. 18: 1187-98. PMID 17823850 DOI: 10.1007/S10552-007-9057-X |
0.362 |
|
| 2007 |
Schairer C, Hisada M, Chen BE, Brown LM, Howard R, Fosså SD, Gail M, Travis LB. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. Journal of the National Cancer Institute. 99: 1248-56. PMID 17686826 DOI: 10.1093/Jnci/Djm081 |
0.37 |
|
| 2007 |
Qu CX, Kamangar F, Fan JH, Yu B, Sun XD, Taylor PR, Chen BE, Abnet CC, Qiao YL, Mark SD, Dawsey SM. Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China. Journal of the National Cancer Institute. 99: 1240-7. PMID 17686823 DOI: 10.1093/Jnci/Djm084 |
0.327 |
|
| 2007 |
Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1683-90. PMID 17404367 DOI: 10.1200/Jco.2006.09.2106 |
0.542 |
|
| 2007 |
Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. American Journal of Epidemiology. 165: 1443-53. PMID 17379617 DOI: 10.1093/Aje/Kwm030 |
0.467 |
|
| 2007 |
Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. Journal of the National Cancer Institute. 99: 215-22. PMID 17284716 DOI: 10.1093/Jnci/Djk030 |
0.37 |
|
| 2007 |
Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fosså SD, Travis LB. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Research and Treatment. 106: 439-51. PMID 17277968 DOI: 10.1007/S10549-007-9509-8 |
0.388 |
|
| 2007 |
Howard RA, Gilbert ES, Chen BE, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa SD, Travis LB. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Research and Treatment. 105: 359-68. PMID 17221155 DOI: 10.1007/S10549-006-9460-0 |
0.36 |
|
| 2007 |
Anderson WF, Matsuno RK, Sherman ME, Lissowska J, Gail MH, Brinton LA, Yang XR, Peplonska B, Chen BE, Rosenberg PS, Chatterjee N, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Devesa SS, et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes & Control : Ccc. 18: 439-47. PMID 17216325 DOI: 10.1007/S10552-006-0092-9 |
0.557 |
|
| 2007 |
Anderson WF, Brinton LA, Chen B, Devesa SS. Qualitative age interactions (or effect modification) suggest divergent pathways for early-onset and late-onset breast cancers Journal of Clinical Oncology. 25: 21036-21036. DOI: 10.1200/Jco.2007.25.18_Suppl.21036 |
0.339 |
|
| 2006 |
Schairer C, Brown LM, Chen BE, Howard R, Lynch CF, Hall P, Storm H, Pukkala E, Anderson A, Kaijser M, Andersson M, Joensuu H, Fosså SD, Ganz PA, Travis LB. Suicide after breast cancer: an international population-based study of 723,810 women. Journal of the National Cancer Institute. 98: 1416-9. PMID 17018788 DOI: 10.1093/Jnci/Djj377 |
0.385 |
|
| 2006 |
Chen BE, Sakoda LC, Hsing AW, Rosenberg PS. Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genetic Epidemiology. 30: 495-507. PMID 16755536 DOI: 10.1002/Gepi.20162 |
0.55 |
|
| 2006 |
Anderson WF, Chen BE, Jatoi I, Rosenberg PS. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Research and Treatment. 100: 121-6. PMID 16685588 DOI: 10.1007/S10549-006-9231-Y |
0.548 |
|
| 2006 |
Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, Deng J, Shen MC, Wang BS, Han TQ, Zhang BH, Cohen-Webb H, Yeager M, Welch R, Chanock S, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis. 27: 1251-6. PMID 16361272 DOI: 10.1093/Carcin/Bgi314 |
0.553 |
|
| 2006 |
Rosenberg PS, Che A, Chen BE. Multiple hypothesis testing strategies for genetic case-control association studies. Statistics in Medicine. 25: 3134-49. PMID 16252274 DOI: 10.1002/Sim.2407 |
0.526 |
|
| 2005 |
Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Disease. 22: 9-23. PMID 16735783 DOI: 10.3233/Bd-2006-22103 |
0.375 |
|
| 2005 |
Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8629-35. PMID 16314625 DOI: 10.1200/Jco.2005.02.9199 |
0.565 |
|
| 2005 |
Chen BE, Cook RJ, Lawless JF, Zhan M. Statistical methods for multivariate interval-censored recurrent events. Statistics in Medicine. 24: 671-91. PMID 15558580 DOI: 10.1002/Sim.1936 |
0.504 |
|
| 2004 |
Chen BE, Cook RJ. Tests for multivariate recurrent events in the presence of a terminal event. Biostatistics (Oxford, England). 5: 129-43. PMID 14744832 DOI: 10.1093/Biostatistics/5.1.129 |
0.478 |
|
| 2003 |
Cook RJ, Chen BE, Major P. Marginal Analysis of Point Processes with Competing Risks Handbook of Statistics. 23: 349-361. DOI: 10.1016/S0169-7161(03)23019-4 |
0.455 |
|
| Show low-probability matches. |